期刊
CELLS
卷 8, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/cells8050472
关键词
CAR T cell; chimeric antigen receptor; immunotherapy; adoptive cell therapy
类别
资金
- international doctoral program i-Target: Immunotargeting of cancer - Elite Network of Bavaria
- Melanoma Research Alliance [N269626, 409510]
- Marie-Sklodowska-Curie Training Network for the Immunotherapy of Cancer(IMMUTRAIN) - H2020 program of the European Union
- Else Kroner-Fresenius-Stiftung
- German Cancer Aid
- Ernst-Jung-Stiftung
- LMU Munich's Institutional Strategy LMUexcellent
- Bundesministerium fur Bildung und Forschung
- European Research Council Starting Grant [756017]
- European Research Council (ERC) [756017] Funding Source: European Research Council (ERC)
Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据